Canada· CA-DIN-02446634
OPDIVO
A nivolumab product containing nivolumab, registered in Canada by BRISTOL-MYERS SQUIBB CANADA. The same ATC class is registered in 13 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Nivolumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FF01 (nivolumab), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 8 of them publish a price we can compare per daily dose
Nivolumab · ATC L01FF01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- NIVOLUMAB
- Manufacturer
- BRISTOL-MYERS SQUIBB CANADA
- Country
- Canada (CA)
- ATC code
- L01FF01
- ATC class
- Nivolumab
- Defined daily dose
- 17.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for nivolumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nivolumab · interactions on record
22 records
- 3 severe
- 19 moderate
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nivolumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainOPDIVO 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- United KingdomNivolumab BMS 100mg/10ml concentrate for solution for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- United StatesOPDIVOE.R. Squibb & Sons, L.L.C.
- FinlandNivolumab BmsBristol-Myers Squibb Pharma EEIG
- BelgiumOpdivo 10 mg/mlBristol-Myers Squibb Pharma
- CzechiaOPDIVOBristol-Myers Squibb Pharma EEIG, Dublin
- SwitzerlandOpdivo 100 mg/10 ml, Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
- Japanニボルマブ（遺伝子組換え）小野薬品工業
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Opdivo
- Liechtenstein · Opdivo
- Norway · Opdivo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c8b79098-5a7c-409e-a327-686310fdbf05 GET /v1/drugs/c8b79098-5a7c-409e-a327-686310fdbf05?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02446634",
"form": "SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01FF01",
"schedule": [
"Schedule D",
"Prescription"
],
"drug_code": "93205",
"strengths": [
"10 MG"
],
"ahfs_class": null,
"substances": [
"NIVOLUMAB"
],
"product_categorization": null
}See everything about nivolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.